Objective - This prospective, open-label study was conducted to evaluate the effectiveness, tolerability, and safety of levetiracetam in patients with epilepsy in whom unfavorable metabolism, complex drug interactions, or direct toxic effects of antiepileptic drugs (AEDs) had caused a worsening of comorbid conditions. Methods - Study design included the introduction of levetiracetam, discontinuation of other AEDs, and a serial assessment comprising electroencephalograms and blood tests at baseline and 2, 6, and 12 months. Of 21 patients, 16 had partial and five generalized epilepsy. Concomitant pathologies were gastroenterological (six), vascular (four), endocrinological (four), or complex conditions including hematological (four) or dermatological (three) disease. A change of regimen was necessitated by drug-drug interactions in four patients, direct real or potential toxic effects of previous AEDs in 13, and a combination of interactions/toxic effects in four. Results - After 12 months, 12 patients were seizure-free, nine had reductions in seizure frequency of 50-75%, and improvement in concomitant medical conditions was observed. No side effects were reported. Conclusion - Levetiracetam appears to be effective, well tolerated, and safe in patients with epilepsy and other medical conditions that are difficult to manage because of drug interactions or AED-related side effects. © Blackwell Munksgaard 2005.

Use of levetiracetam in treating epilepsy associated with other medical conditions / Di Bonaventura, C.; Mari, F.; Fattouch, J.; Egeo, G.; Vaudano, Anna Elisabetta; Manfredi, M.; Prencipe, Michele; Giallonardo, A. T.. - In: ACTA NEUROLOGICA SCANDINAVICA. - ISSN 0001-6314. - 113:2(2006), pp. 82-86. [10.1111/j.1600-0404.2005.00554.x]

Use of levetiracetam in treating epilepsy associated with other medical conditions

VAUDANO, Anna Elisabetta;
2006

Abstract

Objective - This prospective, open-label study was conducted to evaluate the effectiveness, tolerability, and safety of levetiracetam in patients with epilepsy in whom unfavorable metabolism, complex drug interactions, or direct toxic effects of antiepileptic drugs (AEDs) had caused a worsening of comorbid conditions. Methods - Study design included the introduction of levetiracetam, discontinuation of other AEDs, and a serial assessment comprising electroencephalograms and blood tests at baseline and 2, 6, and 12 months. Of 21 patients, 16 had partial and five generalized epilepsy. Concomitant pathologies were gastroenterological (six), vascular (four), endocrinological (four), or complex conditions including hematological (four) or dermatological (three) disease. A change of regimen was necessitated by drug-drug interactions in four patients, direct real or potential toxic effects of previous AEDs in 13, and a combination of interactions/toxic effects in four. Results - After 12 months, 12 patients were seizure-free, nine had reductions in seizure frequency of 50-75%, and improvement in concomitant medical conditions was observed. No side effects were reported. Conclusion - Levetiracetam appears to be effective, well tolerated, and safe in patients with epilepsy and other medical conditions that are difficult to manage because of drug interactions or AED-related side effects. © Blackwell Munksgaard 2005.
113
2
82
86
Use of levetiracetam in treating epilepsy associated with other medical conditions / Di Bonaventura, C.; Mari, F.; Fattouch, J.; Egeo, G.; Vaudano, Anna Elisabetta; Manfredi, M.; Prencipe, Michele; Giallonardo, A. T.. - In: ACTA NEUROLOGICA SCANDINAVICA. - ISSN 0001-6314. - 113:2(2006), pp. 82-86. [10.1111/j.1600-0404.2005.00554.x]
Di Bonaventura, C.; Mari, F.; Fattouch, J.; Egeo, G.; Vaudano, Anna Elisabetta; Manfredi, M.; Prencipe, Michele; Giallonardo, A. T.
File in questo prodotto:
File Dimensione Formato  
DIBONAVENTURA-ACTANEUROLSCANDIV-2006.pdf

non disponibili

Dimensione 102.09 kB
Formato Adobe PDF
102.09 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1268264
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 10
social impact